Cargando…

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis

In recent years, anti-PD-1/anti-PD-L1 has been considered to be a valuable therapeutic target and prognostic indicator for triple-negative breast cancer. We analyzed all publications published in the field from their inception until the present day in order to determine the current research status a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jinyao, Chen, Yaokun, Chen, Lingzhi, Ji, Zeqi, Tian, Huiting, Zheng, Daitian, Yang, Qiuping, Liu, Yiyuan, Cai, Jiehui, Zheng, Jiehua, Chen, Yexi, Li, Zhiyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875294/ https://www.ncbi.nlm.nih.gov/pubmed/36713507 http://dx.doi.org/10.3389/fonc.2022.1002667

Ejemplares similares

Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis
por: Chen, Lingzhi, et al.
Publicado: (2022)

A scientometric analysis of research trends on emerging contaminants in the field of cancer in 2012–2021
por: Zheng, Daitian, et al.
Publicado: (2022)

Global research into the relationship between electronic waste and health over the last 10 years: A scientometric analysis
por: Tian, Huiting, et al.
Publicado: (2023)

Global trends in research of endoscopic thyroidectomy from 2013 to 2022: a scientometric and visualization analysis
por: Zheng, Daitian, et al.
Publicado: (2023)

A scientometric analysis of research trends on targeting mTOR in breast cancer from 2012 to 2022
por: Zhang, Xizhou, et al.
Publicado: (2023)

Global trends in BRCA-related breast cancer research from 2013 to 2022: A scientometric analysis
por: Huang, Yujie, et al.
Publicado: (2023)

Scientometric analysis of lipid metabolism in breast neoplasm: 2012–2021
por: Lin, Xiaobing, et al.
Publicado: (2023)

Trends in research of exosomes associated with breast cancer over the past decade: a scientometric analysis
por: Wu, Jiaxin, et al.
Publicado: (2023)

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis
por: Liu, Yiyuan, et al.
Publicado: (2023)

Research trend of circulating tumor DNA associated with breast cancer from 2012 to 2021: A bibliometric analysis
por: Ji, Zeqi, et al.
Publicado: (2023)

The efficacy of cognitive behavioral therapy for cancer: A scientometric analysis
por: Lin, Chuanghao, et al.
Publicado: (2022)

Mapping global trends in research of stem cell therapy for COVID-19: A bibliometric analysis
por: Zhang, Xinkang, et al.
Publicado: (2022)

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials
por: Li, Zhiyang, et al.
Publicado: (2022)

A bibliometric and visualization analysis on the association between chronic exposure to fine particulate matter and cancer risk
por: Luo, Xuman, et al.
Publicado: (2022)

Reply letter to “Comment on bibliometric and visual analysis of vaccination hesitancy research”
por: Chen, Chaojian, et al.
Publicado: (2023)

Bibliometric and visual analysis of vaccination hesitancy research from 2013 to 2022
por: Chen, Chaojian, et al.
Publicado: (2023)

Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer
por: Cai, Jiehui, et al.
Publicado: (2022)

Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer
por: Lin, Weixun, et al.
Publicado: (2022)

Prognostic and Immune-Infiltrate Significance of miR-222-3p and Its Target Genes in Thyroid Cancer
por: Zhang, Taofeng, et al.
Publicado: (2021)

The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019
por: Xu, Shangbo, et al.
Publicado: (2021)

Global research trends in palliative care for breast cancer from 2012 to 2022: A scientometric analysis
por: Sun, Yixian, et al.
Publicado: (2023)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
por: Li, Zhiyang, et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Jiang, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis
por: Zeng, Yi-Fan, et al.
Publicado: (2023)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

A Low Creatinine to Body Weight Ratio Predicts the Incident Nonalcoholic Fatty Liver Disease in Nonelderly Chinese without Obesity and Dyslipidemia: A Retrospective Study
por: Lin, Jianxiong, et al.
Publicado: (2020)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2022)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
por: Zheng, Xin, et al.
Publicado: (2021)

Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
por: Nakayama, Yuko, et al.
Publicado: (2019)

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
por: Chen, Gang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ckpo2ftclfmn9lkjksmit0hl1j